A Phase I Clinical Study of JS004 in Subjects With Recurrent/Refractory Malignant Lymphoma of China

NCT04477772 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

71

Enrollment

OTHER

Sponsor class

Conditions

Recurrent/Refractory Malignant Lymphoma

Interventions

BIOLOGICAL: JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion
BIOLOGICAL: Drug：JS001, Intravenous infusion

Sponsor

Shanghai Junshi Bioscience Co., Ltd.